Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

16.85
+0.90005.64%
Post-market: 16.850.00000.00%17:36 EST
Volume:836.54K
Turnover:14.02M
Market Cap:1.73B
PE:-5.52
High:17.03
Open:16.29
Low:16.26
Close:15.95
52wk High:22.50
52wk Low:8.18
Shares:102.84M
Float Shares:86.36M
Volume Ratio:0.71
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0514
EPS(LYR):-3.0514
ROE:-49.63%
ROA:-26.30%
PB:3.22
PE(LYR):-5.52

Loading ...

Stock Track | Nurix Therapeutics Plummets 5% Intraday on Q4 Losses and Foreign Exchange Risk Concerns

Stock Track
·
Jan 30

Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress

Simply Wall St.
·
Jan 30

Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure

TIPRANKS
·
Jan 30

Nurix Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 30

Stock Track | Nurix Therapeutics Soars 5.90% in Intraday Trading on Positive Analyst Ratings

Stock Track
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Jan 29

RBC Raises Price Target on Nurix Therapeutics to $30 From $28, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 29

Nurix Therapeutics Price Target Maintained With a $26.00/Share by Needham

Dow Jones
·
Jan 29

Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright

TIPRANKS
·
Jan 29

Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)

TIPRANKS
·
Jan 29

Australia's Nurix Therapeutics Q4 net loss widens

Reuters
·
Jan 29

Nurix Therapeutics Appoints Roger Dansey to Board of Directors

Reuters
·
Jan 29

Nurix Therapeutics Q4 EPS $(0.82) Beats $(0.92) Estimate, Sales $13.577M Miss $14.309M Estimate

Benzinga
·
Jan 29

Nurix Therapeutics Q4 Net Income USD -78.221 Million

THOMSON REUTERS
·
Jan 29

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

GlobeNewswire
·
Jan 29

Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of Common Shares

Reuters
·
Jan 21

RBC Trims Price Target on Nurix Therapeutics to $28 From $29, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 20

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)

TIPRANKS
·
Jan 16

Mizuho Securities Remains a Buy on Nurix Therapeutics (NRIX)

TIPRANKS
·
Jan 14

Do Analyst Upgrades Clarify Nurix Therapeutics’ (NRIX) True Potential Or Complicate Its Valuation Story?

Simply Wall St.
·
Jan 13